Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $65.50M |
| Gross Profit (TTM) | $-371.20M |
| EBITDA | $-451.05M |
| Operating Margin | 459241.00% |
| Return on Equity | -47.70% |
| Return on Assets | -24.80% |
| Revenue/Share (TTM) | $0.47 |
| Book Value | $5.49 |
| Price-to-Book | 1.91 |
| Price-to-Sales (TTM) | 23.66 |
| EV/Revenue | 18.05 |
| EV/EBITDA | 0.90 |
| Quarterly Earnings Growth (YoY) | 58.50% |
| Quarterly Revenue Growth (YoY) | 417.80% |
| Shares Outstanding | $168.65M |
| Float | $128.81M |
| % Insiders | 6.57% |
| % Institutions | 81.18% |
Volatility is currently contracting